207 related articles for article (PubMed ID: 20458280)
21. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
Muñoz M; Martinez-Armesto J; Coveñas R
Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
[TBL] [Abstract][Full Text] [Related]
22. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Robinson P; Coveñas R; Muñoz M
Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
[TBL] [Abstract][Full Text] [Related]
23. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
Munoz M; Recio S; Rosso M; Redondo M; Covenas R
J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
[TBL] [Abstract][Full Text] [Related]
24. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
25. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.
Kolorz J; Demir S; Gottschlich A; Beirith I; Ilmer M; Lüthy D; Walz C; Dorostkar MM; Magg T; Hauck F; von Schweinitz D; Kobold S; Kappler R; Berger M
Curr Oncol; 2021 Dec; 29(1):94-110. PubMed ID: 35049682
[TBL] [Abstract][Full Text] [Related]
26. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines.
Muñoz M; Rosso M; Pérez A; Coveñas R; Rosso R; Zamarriego C; Soult JA; Montero I
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2567-70. PubMed ID: 15980249
[TBL] [Abstract][Full Text] [Related]
27. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro.
Wang X; Douglas SD; Lai JP; Tuluc F; Tebas P; Ho WZ
J Neuroimmune Pharmacol; 2007 Mar; 2(1):42-8. PubMed ID: 18040825
[TBL] [Abstract][Full Text] [Related]
29. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M
Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755
[TBL] [Abstract][Full Text] [Related]
30. Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography.
Endo T; Saijo T; Haneda E; Maeda J; Tokunaga M; Zhang MR; Kannami A; Asai H; Suzuki M; Suhara T; Higuchi M
Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25609595
[TBL] [Abstract][Full Text] [Related]
31. The NK-1 receptor: a new target in cancer therapy.
Muñoz M; Rosso M; Coveñas R
Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668
[TBL] [Abstract][Full Text] [Related]
32. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Investig Drugs; 2007 Dec; 16(12):1977-85. PubMed ID: 18042005
[TBL] [Abstract][Full Text] [Related]
33. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant.
Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH
Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
[TBL] [Abstract][Full Text] [Related]
35. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
36. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
[TBL] [Abstract][Full Text] [Related]
37. Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.
Schwartz L; Spitsin SV; Meshki J; Tuluc F; Douglas SD; Wolfe JH
J Neurovirol; 2013 Jun; 19(3):219-27. PubMed ID: 23765222
[TBL] [Abstract][Full Text] [Related]
38. The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines.
Muñoz M; Rosso M; González-Ortega A; Coveñas R
Cancers (Basel); 2010 Apr; 2(2):611-23. PubMed ID: 24281084
[TBL] [Abstract][Full Text] [Related]
39. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
Muñoz M; Coveñas R
World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
[TBL] [Abstract][Full Text] [Related]
40. Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.
Muñoz M; Coveñas R
Anticancer Agents Med Chem; 2019; 19(1):92-100. PubMed ID: 29692265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]